Clinical trial · Interventional
Biomarker-driven Therapy for Melanoma
Feasibility Study of Biomarker-driven Therapy Based on a Comprehensive Molecular Analysis of Tumor Tissue and Blood Collections in Melanoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients included will undergo biopsy and the molecular analysis will be discussed at the institutional molecular tumor board. The recommandation of the molecular tumor board will be provided to the physician in charge of the patient for final treatment desicion. The main endpoints are the number of patients with actionable molecular alterations, the number of patients with a treatment recommendation, the number of patients receiving the recommended therapy, overall survival of the patients treated according to recommendations or not. For patients treated according to the recommendations: Response rate and progression free survival at 6 months according to RECIST criteria.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular guided therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Molecular guided therapy
- interventionNames
- Drug: Molecular guided therapy
Primary outcomes (3)
- measure
- Feasibility (actionable molecular alterations)
- timeFrame
- Through study completion over 5 years
- description
- number of patients with actionable molecular alterations
- measure
- Feasibility (number of patients with a treatment recommendation)
- timeFrame
- Through study completion over 5 years
- description
- number of patients with a treatment recommendation
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically proven metastatic melanoma failing standard treatments * age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * life expectancy ≥ 24 weeks * adequate renal, liver, and bone marrow functions Exclusion Criteria: \- history of cardiac disease or metastatic brain or meningeal tumors
References
Publications (0)
Data not yet available